2015
DOI: 10.2174/1872214809666150806105737
|View full text |Cite
|
Sign up to set email alerts
|

Resveratrol Pretreatment Ameliorates TNBS Colitis in Rats

Abstract: Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease in humans constituting a major health concern today whose prevalence has been increasing over the world. Production of reactive oxygen species (ROS) and disturbed capacity of antioxidant defense in IBD subjects have been reported. Antioxidants may play a significant role in IBD treatment. This study aimed at evaluating ameliorative effects of intraperitoneal resveratrol pretreatment on trinitrobenzene sulphonic acid (TNBS)-induced co… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
29
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 50 publications
(29 citation statements)
references
References 40 publications
0
29
0
Order By: Relevance
“…In another mouse colitis model using IL-10 −/− mice which develop spontaneous chronic colitis within 18 weeks, resveratrol was able to induce immunosuppressive CD11b + Gr-1 + MDSCs in the colon and suggests an as-yet-unidentified mode of anti-inflammatory action of this plant polyphenol [19]. Similar positive outcomes of resveratrol treatment were demonstrated in various rat colitis and Crohn's disease models including 2,4,6-trinitrobenzene sulfonic acid (TNBS), oxazolone, and peptidoglycan-polysaccharide [2023]. Furthermore, Samsami-Kor et al performed a pilot study on patients with ulcerative colitis showing that 6 weeks of resveratrol supplementation was able to improve quality of life in patients with active colitis at least partially through inflammation reduction.…”
Section: Introductionmentioning
confidence: 92%
“…In another mouse colitis model using IL-10 −/− mice which develop spontaneous chronic colitis within 18 weeks, resveratrol was able to induce immunosuppressive CD11b + Gr-1 + MDSCs in the colon and suggests an as-yet-unidentified mode of anti-inflammatory action of this plant polyphenol [19]. Similar positive outcomes of resveratrol treatment were demonstrated in various rat colitis and Crohn's disease models including 2,4,6-trinitrobenzene sulfonic acid (TNBS), oxazolone, and peptidoglycan-polysaccharide [2023]. Furthermore, Samsami-Kor et al performed a pilot study on patients with ulcerative colitis showing that 6 weeks of resveratrol supplementation was able to improve quality of life in patients with active colitis at least partially through inflammation reduction.…”
Section: Introductionmentioning
confidence: 92%
“…In animal models of IBD, RES administration was very effective in reducing mucosal inflammation via inhibition of malondialdehyde and increase of glutathione peroxidase activities, respectively [239][240][241][242][243][244]. Furthermore, in the above models, decrease in neutrophil infiltration and proinflammatory cytokine release and increase in number of Bifidobacteria and Lactobacilli with reduction of intestinal wall fibrosis have been observed [239][240][241][242][243][244].…”
Section: Allergy and Autoimmune Diseasesmentioning
confidence: 90%
“…In animal models of IBD, RES administration was very effective in reducing mucosal inflammation, inhibiting malondialdehyde and increasing glutathione peroxidase activity; decreasing neutrophil infiltration and pro-inflammatory cytokine release and augmenting number Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 3 December 2019 doi:10.20944/preprints201912.0030.v1 of bifidobacteria and lactobacilli; diminishing expression of COX-2, PGD2, PGE synthase-1 and lowering TGF-1 and fibrosis of the intestinal wall [235][236][237][238][239][240]. RES has been experimented either in vitro or in vivo in rheumatoid arthritis.…”
Section: Allergy and Autoimmune Diseasesmentioning
confidence: 99%